

Press Release

Biofrontera to Present at the Dawson James Securities 2nd Annual Growth Stock Conference

Leverkusen, Germany, October 07, 2016 – Biofrontera AG (FSE: B8F), the specialist for the treatment of sun-induced skin cancer, today announced that it will be featured as a presenting company at the Dawson James 2nd Annual Growth Stock Conference, being held on October 20, 2016 at Wyndham Grand Hotel in Jupiter, FL.

Prof. Hermann Lübbert, Biofrontera's Chief Executive Officer, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

Details for the presentation are as follows:

Date: Thursday, October 20, 2016
Time: 4:00PM EST
Room: Track 1 – Preserve Ballroom C

-Ends-

Enquiries, please contact: Biofrontera AG +49 (0) 214 87 63 2 0
Thomas Schaffer, Chief Financial Officer press@biofrontera.com

IR Germany: Brainwell Asset Solutions +49 (0) 152 08931514
Jürgen Benker

IR UK: Seton Services +44(0) 20 7229 0805
Toni Vallen

IR and PR US: The Ruth Group
IR: Lee Roth / Tram Bui +1 646-536-7012 / 7035
PR: Kirsten Thomas +1 508-280-6592

About Biofrontera

Biofrontera Group (FSE: B8F, ISIN DE0006046113) **Biofrontera** is a biopharmaceutical company specializing in the development, sale and distribution of drugs, medical devices and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is Ameluz[®], a prescription drug which was initially approved and marketed in Europe and is now also approved in the US for the treatment of mild and moderate actinic keratosis, a precursor to squamous cell carcinoma, with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up

Press release

company to obtain centralized EU and now US approval for a medical device/drug it has developed itself.

The company also markets the Belixos® dermatological range of cosmetics. Belixos® products, a cream, a gel, a scalp tonic and acute roll-on, contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. The Belixos® Protect, a daily skincare for sun-damaged skin, complements this dermo-cosmetic line. All products are available through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.

For more information, visit www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.